All GLG News Analyses Filed Under: Ophthalmology
Posted August 31, 2007
Bausch & Lomb: Activist Investor Loeb Discloses a 9% Passive Stake
Analysis of: Bausch & Lomb: Activist Investor Loeb Discloses a 9% Passive Stake | seekingalpha.com
Author: GLG Member Program Contributor
Analysis of: Bausch & Lomb: Activist Investor Loeb Discloses a 9% Passive Stake | seekingalpha.com
Author: GLG Member Program Contributor
- With large hedge funds invovled, B&L management is likely being pressured to accept an all-cash deal. - If SAC is also involved, the pressure on B&L is definitely rising.
Posted August 31, 2007
Aussie Boxing Champion Hospitalized Due To Eye Infection; Doubts About Career Prospects
Analysis of: Aussie Boxing Champion Hospitalized Due To Eye Infection; Doubts About Career Prospects | www.allheadlinenews.com
Author: GLG Member Program Contributor
Analysis of: Aussie Boxing Champion Hospitalized Due To Eye Infection; Doubts About Career Prospects | www.allheadlinenews.com
Author: GLG Member Program Contributor
Boxer Sugar Ray Leonard had a complex retinal detachment, Orlando Brown of football was nearly blinded by a referee's thrown flag. Soft contact lens wear is barely compatible with sweaty, dusty contact sports. Some great basketball players wore (& wear) goggles. Asking boxers to wear...
Posted August 31, 2007
Eyeonics Files For IPO
Analysis of: Eyeonics Files For IPO | www.socaltech.com
Author: GLG Member Program Contributor
Analysis of: Eyeonics Files For IPO | www.socaltech.com
Author: GLG Member Program Contributor
It seems most likely that the reason that the major ophthalmic houses did not want the Crystalens-Eyeonics company is that the technology has substantial problems. Unlike the multifocal lenses, in order to give the best possible distance vision, near vision is not...
Posted August 31, 2007
BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07
Analysis of: BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07 | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07 | www.pipelinereview.com
Author: GLG Member Program Contributor
Biodem (ASX:BDM) is conducting a a Phase I/II trail involving a 10 day course of subcutaneous injection of a peptide in the treatment of diabetic macular edema. The results of this trial which is being conducted abroad in Russia will be available in November 2007. Although promising...
Posted August 31, 2007
Lux granted fast track designation by FDA for LX211 for the treatment of uveitis
Analysis of: Lux granted fast track designation by FDA for LX211 for the treatment of uveitis | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Lux granted fast track designation by FDA for LX211 for the treatment of uveitis | www.pipelinereview.com
Author: GLG Member Program Contributor
LX211, calcineurin inhibitor and antiinflammatory drug, was granted Fast Track designation by the FDA. This move could expedite its approval for the management of non-infectious posterior, intermediate and panuveitis. In a field where there are few approved treatment modalities, this could...
Posted August 30, 2007Eyeonics Going Public
Analysis of: Eyeonics Files For IPO | www.socaltech.com
Author: Mark Packer, Clinical Associate Professor of Ophthalmology OREGON HEALTH & SCIENCE UNIVERSITY - CC
Rather than getting gobbled up by one of the big three players in Ophthalmology (B & L, Alcon and AMO), eyeonics is looking to go it alone into the public arena. The crystalens remains the only approved accommodative intraocular lens, but faces strong competition from the multifocals. ...
Posted August 27, 2007
Advanced Medical Optic's CEO Blames Consumers, Not Complete MoisturePlus, For Increasing Risk of Parasitic Infection
Analysis of: AMO Says the Fault Lies With the Consumers--Not With Complete | westpalmbeach.injuryboard.com
Author: Darcy Ryan, Optometrist Hertzog Eye Associates
Advanced Medical Optic's CEO Blames Consumers, Not Complete MoisturePlus, For Increasing Risk of Parasitic Infection
Analysis of: AMO Says the Fault Lies With the Consumers--Not With Complete | westpalmbeach.injuryboard.com
Author: Darcy Ryan, Optometrist Hertzog Eye Associates
Similar to Bausch & Lomb's reaction to last year's ReNu with MoistureLoc's recall, AMO's CEO has blamed their consumers' poor contact lens hygiene habits for Complete MoisturePlus' recent problems with Acanthamoebic Keratitis. Is there any truth to this statement, or is he just...
Posted August 16, 2007
BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07
Analysis of: BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07 | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07 | www.pipelinereview.com
Author: GLG Member Program Contributor
-diabetes and diabetic retinopathy is on the rise due to an increasing epidemic of obesity
-diabetic retinopathy is the leading cause of blindness in the United States
Posted August 14, 2007
Lux granted fast track designation by FDA for LX211 for the treatment of uveitis
Analysis of: Lux granted fast track designation by FDA for LX211 for the treatment of uveitis | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Lux granted fast track designation by FDA for LX211 for the treatment of uveitis | www.pipelinereview.com
Author: GLG Member Program Contributor
Many horses become afflicted with a severe form of uveitis that may lead to complete blindness. Scientists that have studied this disease believe there is a strong autoimmune component that triggers the progression of symptoms. This clinical condition offers another area where the effectiveness...
Posted August 13, 2007
Tears in the Retinal Pigment Epithelium: A Complication Associated with the New Macular Degeneration Treatments
Analysis of: Tears in the Retinal Pigment Epithelium: A Complication Associated with the New Macular Degeneration Treatments | pt.wkhealth.com
Author: GLG Member Program Contributor
Previous
Page :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next71 to
80
of 210Analysis of: Tears in the Retinal Pigment Epithelium: A Complication Associated with the New Macular Degeneration Treatments | pt.wkhealth.com
Author: GLG Member Program Contributor
Tears of the retinal pigment epithelium (RPE) may develop during the course of anti-VEGF therapy for age-related macular degeneration (AMD) related pigment epithelial detachment (PED), according to a study published in the June issue of Retina. A total of 33 cases of RPE tear after treatment with...
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
www.investor.jnj.com
Longer Lashes in a Tube? Maybe Not
www.nytimes.com
Medicare fees to doctors fall Tuesday
news.yahoo.com
Doctors Say Medication Is Overused in Dementia
www.nytimes.com
Why anaesthetics can make the pain worse
www.newscientist.com
An illegal use of Lumigan, now legal?
July 3, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
June 30, 2008
Obesity: Higher Healthcare Costs, Lower Productivity
June 26, 2008
Best acne care product I've seen.
June 25, 2008
Jeff is in accounting not a healthcare provider.
June 23, 2008

